title: Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?
abstract: Paucity of data has led to a lack of consensus regarding indications for, and risk-benefit ratio of, low molecular weight heparin 'bridging' for cardioembolic prevention in patients with atrial fibrillation (AF) until their INR levels are in therapeutic range. Using a hospital database, we compared AF patients ≥65 years who were bridged (n = 265) with patients who were not bridged (n = 4532) after hospital discharge. Patients who failed to achieve a therapeutic INR within 30 days were excluded. CHADS₂ scores (congestive heart failure, hypertension, age ≥75, diabetes, stroke), bleeding risk and co-morbidity scores were assessed. Unadjusted and adjusted odds ratios for outcome events (death, stroke, hemorrhage and venous thromboembolism (VTE) within 30 days of discharge were compared. Bridged patients, as compared to those not bridged, were younger (74.7 ± 6.6 vs. 78.5 ± 7.7 years), less likely to be white (36 vs. 51%), and less likely to have CHADS₂ scores ≥2 (67 vs. 84%), all P < 0.001. There was no significant difference in bleeding risk (bridged vs. not bridged: 1.5 ± 7 vs. 1.7 ± 6). In logistic models adjusting for age, white race, bleeding risk, CHADS₂ and Comorbidity scores, bridging was significantly associated with lower mortality and a decreased odds ratio for VTE (both P < 0.01) but not for stroke or hemorrhage (both P > 0.80). Although we found insufficient evidence of either lower stroke or greater bleeding risk with bridging, our data suggest the possibility that LMWH bridging in patients with AF is associated with lower risks of VTE and death within 30 days of discharge.
authors.affiliation: Division of Hematology, Montefiore Medical Center, Albert Einstein College of Medicine, 3411 Wayne Ave., Bronx, NY 10467, USA. henny.billett@einstein.yu.edu
authors.forename: Henny H
authors.initials: HH
authors.lastname: Billett
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Scorziello
authors.forename: Emily R
authors.initials: ER
authors.lastname: Giannattasio
authors.forename: Hillel W
authors.initials: HW
authors.lastname: Cohen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D019934:International Normalized Ratio / Q000379:methods; D008297:Male; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight
references.citation: Am J Med. 1998 Aug;105(2):91-9
references.pmid: 9727814
references.citation: J Thromb Haemost. 2005 Dec;3(12):2823-5
references.pmid: 16359528
references.citation: Circulation. 2004 Sep 21;110(12):1658-63
references.pmid: 15364803
references.citation: Med Klin (Munich). 2007 Oct 15;102(10):809-15
references.pmid: 17928964
references.citation: Crit Pathw Cardiol. 2003 Jun;2(2):96-103
references.pmid: 18340326
references.citation: Mayo Clin Proc. 2008 Jun;83(6):639-45
references.pmid: 18533080
references.citation: J Thromb Haemost. 2006 Jun;4(6):1246-52
references.pmid: 16706967
references.citation: J Thromb Haemost. 2007 Nov;5(11):2211-8
references.pmid: 17697140
references.citation: Neurology. 2008 Jul 22;71(4):283-7
references.pmid: 18645167
references.citation: J Thromb Thrombolysis. 2006 Feb;21(1):85-9
references.pmid: 16475048
references.citation: Clin Appl Thromb Hemost. 2009 Dec;15(6):609-12
references.pmid: 19825911
references.citation: Cerebrovasc Dis. 2008;26(2):171-7
references.pmid: 18628615
references.citation: Arch Intern Med. 2004 Jun 28;164(12):1319-26
references.pmid: 15226166
references.citation: J Heart Valve Dis. 2007 May;16(3):285-92
references.pmid: 17578050
references.citation: Arch Intern Med. 2008 Jan 14;168(1):63-9
references.pmid: 18195197
references.citation: J Thromb Haemost. 2007 Aug;5(8):1610-6
references.pmid: 17663733
references.citation: Thromb J. 2004 Apr 1;2(1):3
references.pmid: 15059286
references.citation: Int J Epidemiol. 2000 Oct;29(5):891-8
references.pmid: 11034974
references.citation: JAMA. 2001 Jun 13;285(22):2864-70
references.pmid: 11401607